Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1058 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2025-04-22 (biospace.com)
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development -
Utilizing a fully human platform, the company expands in vitro assays to develop a more translational offering
Read more
2025-04-14 (stockstotrade.com)
Pharma Boom: Charles River Drives Innovation -
Charles River Laboratories International Inc.'s stock has been trading up by 6.21 percent, driven by strong market optimism. Pioneering Drug Discovery: Advancing Lupus Treatment A significant breakthrough for lupus treatment is on the horizon, as Charles River teams up with Valo Health. Utilizing the AI platform, Logica, they have identified a promising product candidate. This…
Read more
2025-04-10 (bisnow.com)
Houston Biotechnology Company Brings Manufacturing Ops Home With New Facility
FibroBiologics expects its Houston manufacturing lab to increase the company's pace of discovering therapeutics and potential cures for chronic diseases.
Read more
2025-04-01 (aacrjournals.org)
A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer | Clinical Cancer Research | American Association for Cancer Research
AbstractPurpose:. Effective treatment for patients with metastatic cancer is limited, particularly for those with colorectal cancer with metastatic liver lesions, in which accessibility to numerous tumors is essential for favorable clinical outcomes. Oncolytic viruses (OV) selectively replicate in cancer cells; however, direct targeting of inaccessible lesions is limited when using conventional intravenous or intratumoral administration routes.Patients and Methods:. We conducted a multicenter, dose-escalation, phase I study of vaccinia virus, TG6002, via intrahepatic artery (IHA) delivery in combination with the oral prodrug 5-fluorocytosine to 15 patients with metastatic colorectal cancer.Results:. Successful IHA delivery of replication-competent TG6002 was achieved, as demonstrated by the virus within tumor biopsies. Functional transcription of the FCU1 transgene indicates viral replication within the tumor, with higher plasma 5-fluorouracil associated with patients receiving the highest dose of TG6002.
Read more
2025-03-26 (nature.com)
Proteostasis and lysosomal repair deficits in transdifferentiated neurons of Alzheimer's disease | Cell Biology
Ageing is the most prominent risk factor for Alzheimer's disease (AD). However, the cellular mechanisms linking neuronal proteostasis decline to the characteristic aberrant protein deposits in the brains of patients with AD remain elusive. Here we develop transdifferentiated neurons (tNeurons) from human dermal fibroblasts as a neuronal model that retains ageing hallmarks and exhibits AD-linked vulnerabilities. Remarkably, AD tNeurons accumulate proteotoxic deposits, including phospho-tau and amyloid β, resembling those in APP mouse brains and the brains of patients with AD. Quantitative tNeuron proteomics identify ageing- and AD-linked deficits in proteostasis and organelle homeostasis, most notably in endosome–lysosomal components. Lysosomal deficits in aged tNeurons, including constitutive lysosomal damage and ESCRT-mediated lysosomal repair defects, are exacerbated in AD tNeurons and linked to inflammatory cytokine secretion and cell death.
Read more
2025-02-10 (stocktitan.net)
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
Hoth Therapeutics teams with OnTargetx R&D for important immunohistochemistry study of HT-KIT, targeting c-Kit receptors in cancer treatment advancement.
Read more
2024-09-24 (openpr.com)
Industrial Microbiology Testing Services Market 2024 By Top Key Players Profiled: Charles River Laboratories, Eurofins Scientific, Intertek Group Plc
Press release - Polaris Market Research & Consulting - Industrial Microbiology Testing Services Market 2024 By Top Key Players Profiled: Charles River Laboratories, Eurofins Scientific, Intertek Group Plc - published on openPR.com
Read more
2024-09-23 (openpr.com)
Cell & Gene Therapy Bioanalytical Testing Services Market Forecast by Key Players: BioAgilytix Labs, Charles River Laboratories, Intertek Group Plc.
Press release - Polaris Market Research & Consulting - Cell & Gene Therapy Bioanalytical Testing Services Market Forecast by Key Players: BioAgilytix Labs, Charles River Laboratories, Intertek Group Plc. - published on openPR.com
Read more
2024-09-12 (frontiersin.org)
Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer
Conclusions: We developed three novel transcriptome-based signatures which define sensitivity for each mFFX components that can be used to rationalize the administration of the mFFX regimen in patients with metastatic pancreatic cancer and could help to avoid unnecessary toxic effects.
Read more